MWM
CRSP icon

Moran Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Moran Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Buy
25,302
+8,717
+53% +$460K 0.04% 345
2025
Q4 		$870K Sell
16,585
-5,112
-24% -$306K 0.03% 367
2025
Q3 		$1.41M Buy
21,697
+8,043
+59% +$462K 0.04% 311
2025
Q2 		$664K Buy
+13,654
New +$528K 0.02% 366

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Moran Wealth Management's CRSP Position: Q1 2026 in Review

Moran Wealth Management increased its CRISPR Therapeutics (CRSP) stake by 53% in Q1 2026, buying an estimated $460K and bringing the position to 25,302 shares worth $1.2M. The position accounts for 0.04% of the portfolio, ranked #345.

Moran Wealth Management first reported a position in CRSP in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.41M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Moran Wealth Management held 25,302 shares of CRISPR Therapeutics worth $1.2M as of Q1 2026.
  • Moran Wealth Management bought 8,717 CRISPR Therapeutics shares in Q1 2026, an estimated $460K.
  • CRISPR Therapeutics made up 0.04% of Moran Wealth Management's portfolio in Q1 2026, its #345 holding.
  • Moran Wealth Management first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Moran Wealth Management's CRISPR Therapeutics position peaked at $1.41M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Moran Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.